Carolina Thomas
Family · Toccoa, GANPI 1316430044
Payments from drug & device makers
Across 328 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$527
- Novo Nordisk$442
- AstraZeneca$334
- Otsuka America Pharmaceutical, Inc.$325
- Pfizer$298
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,171100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 81 | $1,090 |
| Lilly USA, LLC | 33 | $527 |
| Novo Nordisk | 33 | $442 |
| AstraZeneca | 20 | $334 |
| Otsuka America Pharmaceutical, Inc. | 15 | $325 |
| Pfizer | 19 | $298 |
| Sanofi-aventis U.S. LLC | 17 | $281 |
| GSK | 16 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $223 |
| Bayer | 9 | $165 |
| Amgen | 9 | $152 |
| Boehringer Ingelheim | 7 | $122 |
| Novartis | 7 | $104 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $100 |
| Axsome Therapeutics, Inc. | 5 | $74 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $71 |
| Amarin Pharma, Inc. | 3 | $52 |
| Dexcom, Inc. | 3 | $50 |
| Exact Sciences | 3 | $46 |
| Lundbeck LLC | 2 | $46 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Johnson & Johnson | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Shield Therapeutics Inc | 2 | $30 |
| Merck | 2 | $28 |
| Eisai Inc. | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Abbott | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
How this compares
$5,171 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 163 | $193,894 |
| OzempicSemaglutide | 157 | $190,367 |
| EliquisApixaban | 74 | $89,210 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $72,650 |
| JardianceEmpagliflozin | 41 | $55,099 |
| MyrbetriqMirabegron | 68 | $54,747 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $53,385 |
| FarxigaDapagliflozin Propanediol | 52 | $52,207 |
| VraylarCariprazine Hcl | 28 | $42,814 |
| RybelsusSemaglutide | 20 | $42,375 |
| TrulicityDulaglutide | 37 | $39,422 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $36,310 |
| ProliaDenosumab | 21 | $35,790 |
| XareltoRivaroxaban | 21 | $31,502 |
| EntrestoSacubitril/Valsartan | 17 | $24,207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $442 | $246,720188 claims |
| Lilly USA, LLCMounjaro, Trulicity | $527 | $233,315200 claims |
| PfizerEliquis, Premarin | $298 | $94,57587 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $241 | $87,36192 claims |
| Boehringer IngelheimJardiance, Tradjenta | $122 | $66,91852 claims |
| AbbVieVraylar, Linzess, Synthroid | $1,090 | $65,87777 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere | $334 | $57,73165 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $54,74768 claims |
| AmgenProlia | $152 | $35,79021 claims |
| Johnson & JohnsonXarelto | $41 | $31,50221 claims |
| NovartisEntresto | $104 | $24,20717 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $281 | $23,03120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Toccoa
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.